Table 1. Activity of second-line... | American Society of Hematology

Table 1.

Activity of second-line BV-based regimens

Regimen	N	Relapsed (n)	Refractory (n)	PET⁻ rate (%)	ASCT (%)	PFS
Sequential PET-adapted therapy with single-agent BV, followed by combination chemotherapy
BV → augmented ICE⁴³	65	31	34	83†	98	82% at 3 y
BV → salvage therapy⁴⁴	37	13	24	73†	89	72% at 18 mo
BV combinations
BV-bendamustine⁴¹	54	27	27	74	74	63% at 2 y
BV-ICE³⁸*	16	5	11	69	75	Too soon
BV-DHAP³⁹*	12	10	2	90	100	Too soon
BV-ESHAP⁴⁰*	66	26	40	70	92	Too soon
BV-nivolumab⁴⁵	62	34	28	61	87 (68% directly after BV-nivo)	89% at 6 mo

Regimen	N	Relapsed (n)	Refractory (n)	PET⁻ rate (%)	ASCT (%)	PFS
Sequential PET-adapted therapy with single-agent BV, followed by combination chemotherapy
BV → augmented ICE⁴³	65	31	34	83†	98	82% at 3 y
BV → salvage therapy⁴⁴	37	13	24	73†	89	72% at 18 mo
BV combinations
BV-bendamustine⁴¹	54	27	27	74	74	63% at 2 y
BV-ICE³⁸*	16	5	11	69	75	Too soon
BV-DHAP³⁹*	12	10	2	90	100	Too soon
BV-ESHAP⁴⁰*	66	26	40	70	92	Too soon
BV-nivolumab⁴⁵	62	34	28	61	87 (68% directly after BV-nivo)	89% at 6 mo

BV-nivo, BV-nivolumab.

Published only in abstract form thus far.

PET⁻ rate for entire PET-adapted approach (only patients who were PET⁺ after single-agent BV received combination chemotherapy).